Merck Could Strike 30 Billion Deal for Revolution Medicines

oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]

AI Summary: Merck is reportedly in advanced talks to acquire Revolution Medicines—a Redwood City–based cancer drug developer—in a deal that could be worth around $30 billion. A separate report adds speculative color, reinforcing market buzz about this strategic move in oncology.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Merck acquires Cidara’s preventive flu drug for $9.2B / 6 months

Sanofi’s $2.2B Dynavax Acquisition Boosts Vaccine Portfolio / 5 months

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 2 months

Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 3 months

Novartis pays $100M upfront for macrocyclic peptide platform / 3 months